×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALNY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
08:00 am
alny
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Low
Report
Alnylam Pharmaceuticals Announces Changes to Board of Directors
12/1
06:58 am
alny
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value [Yahoo! Finance]
Low
Report
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value [Yahoo! Finance]
11/27
07:22 am
alny
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 [Seeking Alpha]
Low
Report
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 [Seeking Alpha]
11/24
11:47 pm
alny
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback [Yahoo! Finance]
11/21
11:17 pm
alny
Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double [Yahoo! Finance]
Low
Report
Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double [Yahoo! Finance]
11/20
06:58 pm
alny
Abrdn Life Sciences Investors Q3 2025 Commentary [Seeking Alpha]
Low
Report
Abrdn Life Sciences Investors Q3 2025 Commentary [Seeking Alpha]
11/18
11:48 am
alny
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
11/14
04:30 am
alny
How Recent Developments Are Shaping the Alnylam Pharmaceuticals Investment Story [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Alnylam Pharmaceuticals Investment Story [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-2.3%
alnylam pharmaceuticals, inc.
7/31/2025
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
12.4%
alnylam pharmaceuticals, inc.
5/1/2025
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-3.7%
alnylam pharmaceuticals, inc.
2/13/2025
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-1.5%
alnylam pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
04:49 pm
alny
Form 8-K ALNYLAM PHARMACEUTICALS, For: Dec 02
Low
Report
Form 8-K ALNYLAM PHARMACEUTICALS, For: Dec 02
12/1
04:10 pm
alny
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 26 Filed by: Greenstreet Yvonne
Low
Report
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 26 Filed by: Greenstreet Yvonne
11/19
04:05 pm
alny
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 17 Filed by: Fitzgerald Kevin Joseph
Medium
Report
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 17 Filed by: Fitzgerald Kevin Joseph
11/17
04:04 pm
alny
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: Fitzgerald Kevin Joseph
Low
Report
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: Fitzgerald Kevin Joseph
11/14
04:17 pm
alny
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 12 Filed by: Greenstreet Yvonne
Low
Report
Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 12 Filed by: Greenstreet Yvonne
11/12
04:04 pm
alny
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: Greenstreet Yvonne
Low
Report
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: Greenstreet Yvonne
11/5
11:26 am
alny
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
10/30
08:16 am
alny
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
Low
Report
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30
11.4%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
TOP News Decliners
12/17
Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study [Reuters (UK)]
-11.7%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: